The Insight® 100, ArcScan’s FDA 510(k)-cleared precision ultrasound device for imaging and biometry of the eye, has been incorporated into the first of many US clinics. Golden, CO June 07, 2016 — ArcScan, Inc., developer of state-of-the-art ophthalmic visualization technology, announced today that the Insight® 100, ArcScan’s FDA 510(k)-cleared precision ultrasound device for imaging and […]
GOLDEN, CO: May 25, 2016 — ArcScan, Inc., developer of state-of-the-art ophthalmic visualization technology, announced today that it is partnering with Cedars/Aspens, an internationally renowned not-for-profit society of anterior segment surgeon educators, to advance the field of ophthalmic imaging and improve the safety and outcomes of surgical patients. The collaboration will initially focus on further […]
GOLDEN, CO: April 14, 2016 — ArcScan, Inc., the developer of next evolution medical imaging devices, announced today that it has received authorization to CE Mark its proprietary precision ultrasound ophthalmic device, the ArcScan Insight™ 100, for commercial sales across the 30 nation European Economic Area (EEA) and Switzerland. The CE Mark approval follows closely […]
GOLDEN, CO: February 29, 2016 — ArcScan, Inc. announced today the start of a multicenter study to evaluate the intraoperator repeatability and interoperator reproducibility (R&R) of its Insight™ 100 for layered corneal thickness measurements (cornea, epithelium, and temporal epithelium) and anterior segment and lens capsule dimensions (sulcus diameter, anterior chamber depth, capsule thickness, and […]
GOLDEN, CO: February 18, 2016 — ArcScan, Inc., developer of state-of-the-art ophthalmic visualization technology, announces FDA 510(k) clearance for its ArcScan Insight™ 100 precision ultrasound device for imaging and biometry of the eye. Indicated for refractive surgical planning and evaluation of anterior segment pathology, the Insight™ 100 images and measures anterior chamber depth, angle-to-angle width, […]
Calgary, Alberta. December 3, 2015 – Tilting Capital Corp. (the “Corporation” or “Tilting”) (NEX – TLL.H) announces that ArcScan, Inc.(“ArcScan” or “the Company”), its merger partner under its proposed business combination (“Transaction”), has finalized and submitted its premarket notification to FDA for its Insight 100 ophthalmic medical device. “This is a significant milestone for ArcScan […]
In this issue: Letter from the President ArcScan appoints Prof. Dan Z. Reinstein as Chief Medical Officer ArcScan goes public on the TSX Venture Exchange First pre-production units undergoing testing Download the full newsletter here: ArcScan Fall 2015 Newsletter.